Cavalcade of Risk

SURGEON GENERAL’S WARNING: Reading this edition of the Cavalcade of Risk puts you at risk of certain side effects such as: a sudden increase in intelligence; gaining a basic understanding of how health care and health insurance works in the UK and at General Mills; nausea from recent economic news.  This news includes investigating the parallels…

$1.1 billion for Comparative Effectiveness Research

Regarding my post on Monday, Obama’s stimulus package–a.k.a. the American Recovery and Reinvestment Act (ARRA)–includes 1.1 billion dollars for clinical comparative effectiveness research. According to the American Academy of Family Physicians (AAFP), ARRA “allocates $1.1 billion for comparative clinical effectiveness research, including $300 million for the Agency for Healthcare Research and Quality and $400 million each…

Should the U.S. get NICE?

All health services researches know that comparative-effectiveness research is a vital link towards improving quality and decreasing cost.  Comparative effectiveness examines different medical treatments and evaluates which are the most cost effective.  The UK’s NICE (National Institute for Health and Clinical Excellence) publishes clinical appraisals regarding which treatments the NHS should cover. Should the U.S. create a…

Is MediGap efficiently priced?

In 2004, 29% of Medicare enrollees had Medigap coverage.  Are these policies priced efficiently? An NBER paper by Maestas, Schroeder and Goldman (2009) argues that the answer is no.   Prior to July 1992, Medigap was minimally regulated.  With the passage of the Omnibus Budget Reconciliation Act of 1990 (implemented in July 1992), Medigap plans…